A new model-free method was developed and termed the landscape dynamic network biomarker (l-DNB) methodology. The method is based on bifurcation theory, which can identify tipping points prior to serious disease deterioration using only single-sample omics data. Here, we showed that l-DNB provides early-warning signals of disease deterioration on a single-sample basis and also detects critical genes or network biomarkers (i.e., DNB members) that promote the transition from normal to disease states. As a case study, l-DNB was used to predict severe influenza symptoms prior to the actual symptomatic appearance in influenza virus infections. The l-DNB approach was then also applied to three tumor disease datasets from the TCGA and was used to detect critical stages prior to tumor deterioration using individual DNB for each patient. The individual DNBs were further used as individual biomarkers in the analysis of physiological data, which led to the identification of two biomarker types that were surprisingly effective in predicting the prognosis of tumors. The biomarkers
Introduction
Disease progression is a dynamic process that typically occurs nonlinearly from a normal state via the gradual accumulation of small or quantitative changes that eventually result in a drastic or qualitative phenotypic-transition to a disease state. Considerable evidence indicates the presence of critical states, or tipping points just prior to the drastic transition between normal and disease states for many diseases [1] [2] [3] . The tipping point (or pre-disease state) during disease progression is the critical state, wherein reversion to the normal state is still possible and predictive information can be gathered for early-warning signals of imminent disease states ( Figure 1A ). The identification of a tipping point for pre-cancerous states has recently garnered considerable attention [4] . However, identifying the critical state is difficult due to phenotypic and molecular expression similarities to the normal state , which contrasts with the stark differences observed between the disease and normal states. In particular, there are generally no significant differences in these properties between normal and critical states ( Figure 1A ) [1] [2] [3] . Most traditional biomarkers of disease states are identified based on differential expression of molecules between disease and normal states, rather than diagnosing critical states. Therefore, identifying tipping points or pre-disease states is an important challenge in medicine or biology that informs understanding of early-warning signals for the prevention and preemptive treatments of diseases in addition to the molecular mechanisms of complex diseases at a network level [1] [2] [3] . In particular, dynamic network biomarkers (DNB) have been proposed to detect the critical states of many diseases using nonlinear dynamic theory [1] [2] [3] [5] [6] [7] .
DNB are a group of molecules (i.e., genes or proteins) or a molecule module that can signal the presence of a tipping point or critical state just prior to the drastic deterioration associated with complex diseases. There are three necessary prerequisites to discern DNB modules from data and identify tipping points (see Methods). In other words, if a physiological system approaches a critical state, then a DNB module appears and satisfies the three criticality conditions shown in Methods. The appearance of such a DNB module implies the imminent transition from a normal state to a disease state. The DNB module [1] [2] [3] can be obtained by maximizing the DNB score, IDNB in Eqn. (1) :
where SDin is the standard deviation of gene expression in the DNB module, PCCin is the average of absolute Pearson correlation coefficients among genes in the DNB module, and PCCout is the average of absolute Pearson correlation coefficients among genes compared within and outside of the DNB module.
The three components in Eqn.
(1) represent the three criteria for determining criticality (see Methods) during disease progression [1-3, 5, 6] . Generally speaking, strongly collective fluctuations of a group of variables imply the presence of an imminent transition ( Figure 1A ). The DNB method described above has been applied in the analysis of complex diseases and physiological processes by several research groups [1] [2] [3] [5] [6] [7] [8] . However, the DNB method requires multiple samples, which are generally unavailable for individual patients in clinical practices. In addition, despite the solid theoretical basis for the DNB methodology that is derived from nonlinear dynamical theory and statistics, there are problems with computationally detecting DNB members and determining DNB module size, further limiting the application of the method.
Here, a new method is proposed termed the landscape DNB (l-DNB) that can be 
Results
Identifying DNB modules in a single sample using the l-DNB method
Using n samples as the reference samples or data [10] that represent the expression data for m genes, the identification of DNBs within a single sample by l-DNB can be performed with the following three steps ( Figure 1B , Figure S19 and Methods).
Step-1. Construction of a single sample network (SSN) for the given sample (see Methods).
Step-2. Calculation of the local DNB score for every gene in the dataset. Using the three criteria for criticality [1, 3, 11] , the local DNB score, Is (x), is calculated using Eqn. (8) (see Methods) for the local module centered at gene x, where the local module is gene x and its first-order network from the single-sample network (SSN) [10] , with x=1,…,m.
Step-3. Identification of the DNB module for the single sample. Overall local DNB scores are used to form a landscape, from which DNB genes (or the DNB module) and the global DNB score, IDNB, can be obtained for the sample or subject. Here, the DNB genes or DNB module are those genes with the highest-k local DNB scores, Is(x), and the global DNB score, IDNB, is defined as After the Is(x) of every gene x is obtained from its corresponding module in SSN, all of the genes are ranked in descending order by scores ( Figure 1B ), which provides a landscape of local DNB scores ( Figure S2 ). The top-k genes in the ranked list can be regarded as the potential DNB members for the single sample, and the corresponding global DNB score can be simply estimated by averaging Is over these top-k genes. Thus, the tipping point of the disease state can be quantified with the corresponding DNB in a reliable and systematic manner without clustering algorithms or other heuristic procedures ( Figure S19 ). The sample with the highest IDNB score among all of the samples is considered to be in the critical state or otherwise near the tipping point.
Detecting early-warning signals of influenza virus infection with l-DNBs
The GSE30550 dataset comprises time series data for the influenza virus infection process [9] and was obtained from the GEO database to validate the detection of early-warning signals prior to disease onset using l-DNB (see Supplementary Methods). Within the dataset, 17 healthy human volunteers were inoculated with H3N2 influenza virus, and gene expression profiles in host peripheral blood samples were examined at 16 time points for each individual ( Figure S3 ). Nine of the 17 volunteers (subjects) developed severe influenza symptoms, while the remaining eight did not [9] .
SSNs were constructed and the Is values were calculated for every gene ( Figure   1B ) at each time point within each sample using reference data representing gene expression data from all of the volunteers at the -24 hour time point (24 hours before viral inoculation, Figure S3 ). The 20 highest ranked genes by Is values were considered the DNB for each subject (i.e., individual biomarkers or individual DNBs for the sample) in each time point. Subsequently, the average Is value for the 20 top ranked genes (i.e., the IDNB) was defined as the global DNB score. The high score corresponds to an early-warning signal for disease state ( Figure 2 ). The l-DNB scores for the nine symptomatic subjects drastically increased before the appearance of influenza symptoms (Figure 2A ), and the scores for the eight non-symptomatic subjects remained stable and low throughout the experiment ( Figure 2B ). Thus, the early-warning disease signals for the respective DNBs for influenza symptoms were detected in the nine symptomatic subjects at least eight hours before the appearance of influenza symptoms, while no significant signal was observed in the eight non-symptomatic subjects ( Figure 2B and 2C). Note that the DNB genes of each subject were generally dissimilar (Table S1 ), indicating the presence of individual biomarkers for each subject rather than biomarkers that are common across all of the subjects. Enrichment analysis of high-frequency genes appearing in at least four DNBs (or subjects) indicated that the high-frequency genes were associated with some immunity-related biological processes annotated in the Gene ontology database (http://www.ebi.ac.uk/QuickGO) including "immune response"
(GO:0006955), "regulation of lymphocyte mediated immunity" (GO:0002706), and "regulation of adaptive immune response" (GO:0002819). These observations are consistent with the process of viral infection. Critical states can certainly be detected in more than one time point for a sample, as was observed for volunteers s6, s12, and s13 ( Figure 2C ). Similar results were obtained when using the 30 highest-ranked genes in the Is list as the DNB ( Figure S4 ), implying that l-DNBs can robustly identify pre-disease states and accurately detect early-warning signals for influenza viral infections. Therefore, the l-DNB method can be used to identify the critical states of diseases in a reliable and systematic manner using individual DNBs based on expression data from one sample taken in a clinic.
Identifying critical states in tumors with l-DNB
The l-DNB methodology was further applied to investigate three tumor-associated gene expression data sets for lung adenocarcinoma (LUAD), Figure 3D ). Moreover, the survival times of samples after the critical state were significantly shorter than for samples before the critical state ( Figure 3D ). There were no significant differences in survival curves among samples in stages IA, IB, and IIA (the stages prior to the critical state) (p = 0.7561; Figure S6A ). In addition, there were also no significant differences in survival curves among samples in stages IIIA, IIIB, and IV (the stages after the critical state) ( p = 0.47515; Figure S6B ). The survival times of samples in stage IIIA were significantly shorter than for samples in stage IIB (p = 0.0087; Figure S7 ). These results indicate the sudden deterioration of survival times in patients with LUAD after the IIB stage, strongly implying that the IIB stage is the disease state tipping point.
l-DNB analyses also identified the tipping point/critical state for THCA disease states as stage III ( Figure 3B ), after which significant tumor deterioration occurred. The survival curves for samples before and after the critical state of THCA were significantly different (p = 5×10 -5 ; Figure 3E ). Accordingly, the survival times of samples after the critical state were significantly shorter than for samples prior to the critical state ( Figure 3E ). In addition, the critical state/tipping point for tumor deterioration in KIRC was identified in stage II ( Figure 3C ). The survival curves for samples before and after the KIRC critical state were significantly different (p ~ 0; Figure 3F ). Accordingly, survival times of samples after the critical state were significantly shorter than for samples before the critical state ( Figure 3F ). Taken together, the results provided here demonstrate that l-DNB can identify the critical states associated with disease deterioration in cancers.
.
Prognostic prediction of tumors using l-DNB
In addition to identifying critical states, l-DNB is effective in predicting prognoses.
Indeed, DNB members could be categorized into two types of molecules for prognostic prediction as common biomarkers for all of the samples: those for samples with poor prognosis termed pessimistic biomarkers, and those with good prognosis termed optimistic biomarkers. Additional details for these identifications are provided in the Supplementary Methods
If pessimistic biomarkers appeared in a sample's DNB, then the prognosis for the sample would be more pessimistic than for other samples. Likewise, if optimistic biomarkers were detected in the DNB of a sample, the prognosis for the sample would be more optimistic than for others.
A total of 11 genes were identified as pessimistic biomarkers for LUAD ( Figure   4G and Figure S8 ), while 3 were identified as optimistic biomarkers ( Figure 4G and Figure S9 ). The survival times of the samples identified with pessimistic biomarkers for LUAD were significantly shorter than for other samples (p ~ 0; Figure 4A ). Further, significantly longer survival times were observed for samples identified with optimistic biomarkers for LUAD than for other samples (p = 0.01008; Figure 4B ). Thus, if one or more pessimistic biomarker genes were present in the DNB of the subject's sample, they would have a shorter survival time, while the converse was true for those samples with optimistic biomarkers.
To test the predictive power of DNB members, we separated samples identified with pessimistic biomarkers into three groups. The three groups exhibited with only one , at least two, and at least three pessimistic biomarkers in their DNBs, respectively. in the survival times of group-2 were shorter than those for group-1 ( Figure S10A ), although the difference was not statistically significant (p = 0.0513). In addition, the survival times for group-3 were shorter than those of group-1 ( Figure S10B ) and this difference was statistically significant (p = 0.00768). These results indicate that when more pessimistic biomarker genes were present in the DNB of a patient, shorter survival times would be expected for the patient. Hence, the pessimistic and optimistic biomarkers for LUAD can be used to provide accurate prognosis or predict survival times in patients with LUAD.
In addition, six pessimistic biomarker genes ( Figure 4G and Figure S11 ) and two optimistic biomarker genes ( Figure 4G and Figure S12 ) were identified for THCA.
The survival times of samples identified with pessimistic biomarkers for THCA were significantly shorter than those for other samples (p ~ 0; Figure 4C ).
Conversely, significantly longer survival times were observed for samples identified with optimistic biomarkers for THCA than for other samples (p = 0.00028; Figure 4D ). Thus, the pessimistic and optimistic biomarkers for THCA can be used to make accurate prognoses and estimate survival times for patients with THCA.
Lastly, eight pessimistic biomarker genes ( Figure 4G and Figure S13 ) and seven optimistic biomarker genes ( Figure 4G and Figure S14 ) were identified for KIRC.
As in the above analyses, pessimistic biomarkers for KIRC can be used to identify potentially shorter survival times in patients with KIRC, while optimistic biomarkers for KIRC can be used to identify potentially longer survival times. The samples with pessimistic biomarkers exhibited shorter survival times than did other samples (p ~ 0; Figure 4E ), and samples with optimistic biomarkers exhibited longer survival times than did other samples (p ~ 0; Figure 4F ).
Discussion
The l-DNB methodology described here represents a novel approach to reliably and accurately identify critical states and detect early-warning signals of complex diseases on a single-sample basis. In this study, the l-DNB algorithm was developed to identify individual DNBs from single samples, and the ability of l-DNB to detect early-warning signals for four different diseases, namely, influenza, LUAD, THCA, and KIRC, was validated. The l-DNB approach described here can be used to detect local criticality score or local DNB score for every gene within a sample, and the 20 to 50 top rank genes are empirically considered as the suitable DNB size in a sample. Consequently, DNB can be robustly obtained using l-DNB for any single sample, wherein higher DNB scores indicate a higher risk for health deterioration or an imminent disease status for the subject.
Application of individual DNBs to clinical data indicated that DNB members are
effective for prognostic analyses, as evinced by the identification of pessimistic and optimistic biomarkers for LUAD, THCA, and KIRC disease states that can be used to evaluate patient prognosis for each of the three diseases. Accordingly, if a patient's DNB included pessimistic biomarkers, the patient was likely to have shorter survival times. Moreover, greater numbers of pessimistic biomarkers in patient DNBs correlated to shorter patient survival times. Conversely, if a patient's DNB included optimistic biomarkers, the patient would be expected to have longer survival times. Importantly, some biomarkers indicated in Figure 4G have been previously associated with their corresponding tumors. For example, down-regulation of insulin-like growth factor 4 (INSL4) appeared to contribute to a slower growth rate and loss of tumorigenic properties in a cell line of lung adenocarcinoma [12] . Likewise, down-regulation of Alpha-fetoprotein (AFP) has been reported to result in lung adenocarcinoma [13, 14] . Some of the biomarkers identified here were related to other cancers and have not been previously reported to be associated with LUAD, THCA or KIRC. For example, SOX15 is related to pancreatic tumors, esophagus tumors, and embryonal cell carcinoma [15] [16] [17] , while CXCL5 is related to laryngeal cancer and glioma [18, 19] , and TLX1
is related to leukemia [20, 21] . Nevertheless, most of the biomarkers indicated in Figure 4G have not been previously reported in association with any tumor disease state. Thus, the pessimistic and optimistic biomarkers identified here could be important targets for future research into the molecular mechanisms underlying tumor onset or disease state deterioration. Four genes (PSG3, AFP, and ADH4 in LUAD, in addition to SPANXN3 in KIRC) were identified as pessimistic biomarkers, but were actually not differentially expressed between the identified and unidentified samples (Table S2) , and thus they cannot be detected by traditional methods that rely on differential expression patterns.
This result implies that the l-DNB method can reveal "Dark Matter" [22, 23] genes (i.e., those without differential expressions) that are usually ignored by traditional analyses.
Importantly, the method proposed here is model-free and does not require learning processes to identify biomarkers, which represents an advantage over traditional classification or machine learning methods that require a large number of case/control samples for supervised or unsupervised learning, in order to avoid overlearning issues. Specifically, the l-DNB method is constructed from three model-free DNB conditions for each sample that are based on the essential dynamical features of critical states for general biological systems.
Consequently, the method inherently identifies individual biomarkers rather than common biomarkers without overlearning problems. It should be noted, however, that the identification of common biomarkers or identifying a common threshold of criticality across all of the individuals for each disease may require data for whole populations.
The l-DNB method is also robust with respect to reference samples owing to the mechanisms underlying SSN construction, which has been discussed in detail previously [10] . Specifically, similar l-DNB rankings can be obtained from SSNs for a single sample with different reference samples. Thus, similar l-DNB rankings can be obtained from different samples with similar network structures.
Moreover, the differential network (differential PCC) between any two samples eliminates common components, including those of the reference samples, thereby further reducing the influence of reference samples on outcomes.
However, when reference sample size are small (e.g., < 10), they may significantly impact rankings. Additional details of validation from other independent datasets and other SSN method are provided in the Supplementary Information.
Conclusion
The l-DNB method proposed here can quantify early-warning signals for disease states on a single sample basis prior to disease onset or disease states deterioration. Moreover, the method can be used to identify effective network biomarkers that can predict the prognosis of each cancer patient. Consequently, the methodology has great potential for direct application in preventive and personalized medicine [27] [28] [29] [30] . Specifically, the l-DNB method can detect DNBs systematically without clustering algorithms or other heuristic procedures that have previously been used. Hence, it can be directly applied to personalized pre-disease diagnosis and also the analysis of molecular mechanisms associated with disease progression at the network level. Similarly, the l-DNB method could also be used to detect critical states of many nonlinear biological processes, including cellular differentiation and cellular proliferation [1-3, 5-6].
Methods

The three criteria for DNB identification
The DNB theory is provided in Supplementary Methods and is based on the premise that when a biological or physiological system approaches a critical state from a stable normal state, a DNB module or a group of molecules (i.e., variables) appears and satisfies the following three statistical conditions [2, 4] : 
Construction of single sample networks
Given n reference samples, the Pearson correlation coefficient (PCC) between genes x and y in the reference sample data can be calculated as 
where xi and yi are the expression value for genes x and y for the ith sample in the reference samples, respectively. ̅ and ̅ are the average gene expression values of genes x and y in the reference samples, respectively.
( , ) is the correlation between genes x and y in the n reference samples.
After a new sample is added to the reference sample set ( Figure S1 ), a new PCC is calculated for the two genes using Eqn. (2) based on the total n+1 samples (i.e., n reference samples and the one new sample d) as +1 ( , ) . The difference between PCCn+1 and PCCn for the two genes is due to the new sample addition to the reference data ( Figure S1 ), and hence characterizes the correlation between this sample and the n reference samples. Thus, the single-sample PCC (sPCC) of the two genes x and y against the n reference sample is defined as follows [10] :
which actually represents a differential PCC, or a perturbed PCC of this sample against the reference samples. Since PCCs follow a t-distribution, sPCCn in Eqn. (3) follows the differential PCC distribution with consecutive samples. The statistical significance of sPCCn can be accurately evaluated using the volcano distribution derived from the distribution of the n reference samples or via single-sample network theory [10] . Thus, the distribution of sPCCn depends on both the PCCn and n values.
To reduce computational complexity, an approximation scheme can be used to estimate the significance of sPCCn of Eqn. (3) . Specifically, by assuming a Gaussian distribution with a sufficiently large n, a "Z" score can be calculated for each sPCC, and the p-value of each sPCC can be approximated from the standard normal cumulative distribution [24] based on the "Z" scores [10] .
Single sample networks (SSNs) can then be identified based on significant sPCCs among all of the pairs of genes or molecules that are perturbed by the single sample, while this network also characterizes the single sample [10] . Further, the sPCCn for the SSN can be directly used as an approximation without significance tests. In addition to using the differential sPCC values of Eqn. (3), SSNs can also be constructed using correlation-like edge of each sample (Supplementary Methods) [25] [26] .
Estimating deviation in a single sample
Given n reference samples (i.e., the normal or control sample dataset), the distribution of each gene's expression can be obtained as its reference distribution. The expression of a gene in a new sample d (e.g., a case sample for statistical testing), can be compared with its reference distribution to estimate the deviation of its expression from the reference samples (n samples). The standard deviation of gene expression in the new sample can be expressed as the deviation from expectation based on its reference distribution ( Figure S1 ). as
According to Condition 1 of DNB identification, the deviation of gene x expression in a single sample against its expression in the n reference samples, i.e., the single-sample Expression Deviation (sED), can be defined as: 
Estimating correlation in a single sample
If n is sufficiently large, |PCCn| is considered to be larger than |sPCCn| (i.e., 
Here, sPCCout for the local module of gene x is proportional to the average value of sPCCn between the first-order neighbors, Nxd, and the second-order neighbors, 
where Is(x) is the score for the local module of gene x based on the single sample.
In addition, the local DNB score Is(x), for each gene x can be considered as the criticality score for the gene, and can thus be used to rank the importance of genes contributing to the criticality of the whole dynamic physiological system. 
